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Abstract  
 
Objective: To assess short to medium term cancer control rates and side effects of 
focal salvage High Intensity Focused Ultrasound (HIFU). 
 
Materials and methods: A retrospective registry analysis identified 150 men who 
underwent focal salvage HIFU (Sonablate 500) (November 2006-August 2015). 
Metastatic disease was excluded using the nodal assessment on the pelvic MRI, a 
radioisotope bone scan and PET imaging (choline-FDG-PET or Choline PET-CT).  
In our current clinical practice, metastatic disease must be ruled out by both 
Choline PET and bone scan. Localisation of cancer was by multi-parametric 
prostate MRI (T2W, diffusion-weighting, dynamic contrast enhancement) with 
systematic or template prostate mapping biopsies.  
 
Primary outcome was a composite failure incorporating biochemical failure (BF) 
and/or positive localised or distant imaging and/or positive biopsy and/or systemic 
therapy and/or metastases/prostate cancer specific death. Secondary outcome 
was  BF using the Phoenix-ASTRO definition (nadir+2ng/ml). We used Kaplan-
Meier analysis and Cox-proportional hazards regression to quantify the effect of 
the determinants on the endpoints.  
 
Results: Mean age at focal salvage therapy was 69.8 years (SD 6.1) and median 
PSA pre-focal salvage treatment was 5.5 ng/ml [IQR 3.6-7.9). Median follow-up 
was 35 months (IQR 22-52). Patients were classified as low 2.7% (4/150), 
intermediate 39.3% (59/150) and high-risk disease 41.3% (62/150) according to 
D’Amico classification, prior to focal salvage HIFU.  
Composite failure occurred in 61% (91/150) and BF occurred in 51.3% (77/150). 
The Kaplan-Meier composite endpoint free survival (CEFS) at 3 years was 40% 
(95% CI 31-50) for the entire group. Kaplan-Meier estimates of CEFS were 100%, 
49% and 24% at 3 years in low, intermediate and high D’Amico risk groups pre-
salvage, respectively. The Kaplan-Meier biochemical disease free survival (BDFS) 
at 3 years was 48% (95% CI 39-59) for the entire group. Kaplan-Meier estimates of 
BDFS was 100%, 61% and 32% at 3 years in low, intermediate and high D’Amico 
risk groups pre-salvage, respectively. Complications included urine infection 
(11.3%; 17/150), bladder neck stricture (8%; 12/150), recto-urethral fistula after 1 
HIFU procedure (2%; 3/150) and osteitis pubis (0.7%; 1/150). 
 
Conclusion  
Focal salvage HIFU confers a relatively low complication and side-effect rate. 
Composite endpoint free survival and biochemical control in the short to medium 
term is reasonable, especially in this relatively high risk cohort but still on the lower 
end compared to current whole gland salvage therapies. Focal salvage therapy 
may offer disease control in high risk men whilst minimising additional treatment 
morbidities. 
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Introduction 
Up to half of the patients who have localised prostate cancer treated with 
radiotherapy may experience biochemical failure (BF) by 5-10 years (1-3)  . Due to 
inadequate patient selection, most patients are treated with androgen deprivation 
therapy, a palliative treatment strategy which carries significant side-effects (2,4-6) 
. When curative salvage was possible, whole-gland salvage therapies were usually 
performed. These salvage therapies include radical prostatectomy (RP), 
brachytherapy, cryosurgery, and high intensity focused ultrasound (HIFU). 
Biochemical disease free survival at five years have been reported of up to 82%  . 
However, these therapies carry significant side effects such as urinary 
incontinence  (21-90%), impotence (in those who still have erections) (100%) and 
rectal injury (9.2%) (2,6).Focal salvage therapy aims to treat the area of recurrent 
disease rather than the entire prostate gland. A recent review  has shown 
promising biochemical control rates and side-effects of such experimental focal 
strategies, including strategies considered experimental by the European 
Assoication of Urology (EAU): cryotherapy and HIFU.  
  
Our aim was to assess cancer control rates and genito-urinary and rectal 
complications of focal salvage HIFU treatment. 
 
Materials and methods 
Patient Selection 
 
Independent prospective academic HIFU registry analysis at two centres 
(University College London Hospitals and NHS Basingstoke Trust) identified 150 
men who underwent focal salvage HIFU (November 2006-August 2015). These 
patients’ records were retrospectively reviewed to obtain data from their external 
referral centre, on disease localisation, treatment and follow up. Institutional review 
board exemption was granted by UCH/UCL Joint Research Office. To be eligible 
for focal salvage HIFU, all patients must have experienced biochemical failure 
according to the Phoenix definition (PSA nadir + 2.0 ng/ml) before subsequent 
diagnostic modalities were adopted.  
 
Disease Localization 
 
Before patients are considered for salvage treatment at our institutions, metastatic 
disease must be ruled out using bone-scan and PET imaging (choline-FDG-PET or 
Choline PET-CT) and pelvic MRI for nodal staging. There were no restrictions 
placed on upper level of PSA or PSA kinetics provided the imaging scans 
confirmed T3bN0M0 or less. We included T3b provided less than 1cm of the 
seminal vesicle was involved. Disease was localized using prostate mp-MRI 
studies. As discussed in our previous paper (7,8), each prostate was divided into 
four sectors in three sections (base, mid-gland, apex) with the urethra as the 
anatomical dividing point between right and left and anterior and posterior. Each of 
the 12 resulting sectors and seminal vesicles were scored using the five-point 
Likert scale (1, highly likely no tumour; 5, highly likely tumour) . The sequences 
were evaluated in the following manner. First, the T2 sequences were used to 
provide morphology and anatomical localisation. DCE played a greater role for the 
peripheral zone with the additional reference of the DWI scans. A score of 1 or 2 
was given if there was no enhancement; a score of 3 was given if symmetrical 
diffuse enhancement was seen; if there was focal or asymmetrical enhancement 
≥3 mm and no abnormality seen on DWI, a score of 4 was given; if there was focal 
or asymmetrical enhancement ≥3 mm and/or corresponding DWI abnormality in 
the same anatomical location, a score of 5 was recorded. A similar technique was 
used to report lesions in the transition zone, with DWI sequences given greater 
weighting compared with DCE. DCE shows more enhancement of adenomas in 
this zone, especially after radiotherapy. However, an equivocal score of 3 based 
on DWI could be upgraded to 4 or 5 if there was an associated obvious DCE 
abnormality in the same anatomical location . 
Patients then had either systematic transrectal ultrasound (TRUS) guided biopsies 
or transperineal template prostate mapping (TPM) biopsies using a 5-mm sampling 
frame. The group who had been diagnosed via TRUS biopsy underwent hemi-
ablation salvage HIFU when mp-MRI showed a unifocal recurrence at the same 
site as the positive biopsy. This extended treatment volume was adopted because 
of insufficient location assessment with systematic TRUS-guided biopsies and the 
subsequent difficult matching with the recurrence location on MRI.  
 
HIFU Treatment  
 
This has been described in a previous paper (9). In summary using the Sonablate 
500 transrectal HIFU device (Sonacare Inc, Sonablate 500, Focus Surgery, 
Indianapolis, IN, USA), treatment was either focal (quadrant) ablation, 
hemiablation, or index lesion ablation (Figure 1). Index lesion ablation was 
performed if there was multifocal cancer; any untreated areas had ≤1 core with 
≤3mm Gleason 3 + 3 disease (on TPM) and/or no lesion on mp-MRI. A margin of 5 
mm was adopted around the MRI-based tumour delineation. 
Following treatment men had either a suprapubic catheter placed for 2 to 6 weeks, 
depending on individual patient voiding, or a urethral catheter for 7 to 10 days. Men 
received ciprofloxacillin antibiotics for 7 days postoperatively. Patients with a rise in 
PSA after primary focal salvage HIFU and a localised recurrence based on mp-
MRI and/or TPM-biopsies were eligible for a second focal salvage HIFU treatment.  
 
Follow-Up 
 
Clinical visits occurred every 3 months to record adverse events and the serum 
PSA level. Validated questionnaires were issued to all men and included the 
International Prostate Symptoms Score (IPSS), the University of California Los 
Angeles-Expanded Prostate Cancer Index Composite (UCLA-EPIC) Urinary 
domain, and the International Index of Erectile Function-5 point scale (IIEF-5) 
(10,11) . A higher IPSS indicates worsening symptoms, a lower UCL-EPIC score 
indicates worsening symptoms, and a lower IIEF-5 indicates worsening erectile 
function. 
 
Any 2 consecutive rises in PSA were investigated using mp-MRI and further 
biopsies if MRI was positive and/or staging scans including bone-scan or Choline 
PET/CT or both.  
 
Outcome, measurements and statistical analysis: 
Primary outcome was a composite failure rate following 1 or 2 focal salvage HIFU 
procedures (BF and/or positive localised or distant imaging and/or positive biopsy 
and/or systemic therapy and/or metastases and/or prostate cancer-related death), 
The secondary outcome consisted of BF using the Phoenix-ASTRO definition 
(nadir+2ng/ml) following 1 or 2 focal salvage HIFU procedures, and complications/ 
side-effects.  
 
We also assessed several factors predicting failure including baseline (before 
primary radiotherapy) D’Amico risk group, PSA, T-stage, Gleason score, EBRT 
dose and ADT-use. Factors before focal salvage HIFU included PSA-nadir after 
primary radiotherapy, T-stage, prostate volume on MRI, Gleason score, Maximum 
Cancer Core Length (MCCL), PSA, PSA Doubling time (PSADT), ablation type 
(hemi/focal/index lesion ablation), ADT-use and residual cancer left untreated. 
PSA-nadir post focal salvage HIFU was assessed as post-treatment factor.  
 
Statistics 
 
Model development: Cox-proportional hazards regression was used to quantify the 
effect of the determinants described above on the endpoints. Hazard ratios (HRs) 
with 95% confidence intervals (CI’s) are provided. Factors with p<0.05 were 
included in the multivariable model. The R language environment (version 3.2.1) 
(available at http://www.r-project.org/) (12) was used for all statistical analyses. A 
more elaborate description of the statistical methods used is further discussed in 
the appendix. 
 
 
Results 
 
150 men had focal salvage HIFU for radiorecurrent prostate cancer between 
November 2006 and August 2015 (Table 1 and 2). 20.7%, 23.3% and 42.0% had 
low, intermediate and high risk prior to radiotherapy (14% missing). 96.7% had 
external beam radiotherapy and 3.3% had external beam radiotherapy with an 
HDR brachytherapy boost. Radiation doses of 64 Gray in 32 fractions were the 
most common (n=27). Median time to BF from primary radiotherapy was 80 
months (95% CI 72-86 months). Mean age at focal salvage therapy was 69.8 years 
(SD 6.1) and median PSA pre-focal salvage treatment was 5.5 ng/ml [IQR 3.6-7.9). 
Prior to focal salvage HIFU metastatic disease was ruled out by bone scan or 
Choline PET/FDG scan. Some men did have a Choline FDG scan. However this 
was earlier in the series and clinical practice changed to performing Choline PET-
CT instead of Choline FDG scans.  All men had an mpMRI and either template 
prostate mapping (n=104) or TRUS biopsy (N=40) (with one patient undergoing 
MRI-guided biopsies) (Table 2).  From May 2012 onwards, most patients 
underwent TPM-biopsies (≈85%), while this was approximately 65% before that 
time. The choice of biopsy was made at the discretion of the treating physician, but 
a clear temporal trend to more TPM-biopsies is observed.  
Low, intermediate and high risk disease using D’Amico classification, was present 
in 2.7% (4/150), 39.3% (59/150) and 41.3% (62/150) prior to focal salvage HIFU 
(missing 25. 16,7%).  Three forms of ablation were performed (Table 3): focal 
ablation (55%; 82/150), hemi-ablation (34%; 51/150), and index lesion ablation 
(11%; 17/150). 45.3% (68/150) were on ADT (anti-androgen) for their treatment 
and this was discontinued 6-8 weeks post HIFU. A total of 13 patients received a 
second focal salvage HIFU procedure for a localised recurrence after primary focal 
salvage HIFU. The recurrence was based on mp-MRI and TPM-biopsies in 4 
patients, TPM-biopsies with negative MRI in 2 patients, only mp-MRI in 4 patients 
and only TPM-biopsies in 3 patients.  
 
Primary outcome 
61% (91/150) met failure by the composite outcome. The Kaplan-Meier composite 
endpoint free survival (CEFS) at 3 years was 40% (95% CI 31-50) for the entire 
group. Kaplan-Meier estimates of CEFS was 100%, 49% and 24% at 3 years in 
low, intermediate and high D’Amico risk groups pre-salvage, respectively. When 
assessing CEFS in PSA responders (PSA post-treatment ≤0.5 ng/ml) alone, 
estimated CEFS at 36 months was 67% (95%CI 53-82). 
 
Secondary outcomes 
BF occurred in 51% (77/150). The Kaplan-Meier biochemical disease free survival 
(BDFS) at 3 years was 48% (95% CI 39-59) for the entire group. Kaplan-Meier 
estimates of BDFS was 100%, 61% and 32% at 3 years in low, intermediate and 
high D’Amico risk groups pre-salvage, respectively. 43.3% of patients (65/150) 
were PSA responders; achieving a PSA nadir of ≤0.5, 59.3% (89/150) of men 
achieved a nadir of ≤1ng/ml. When assessing BF in PSA responders alone (PSA 
nadir ≤0.5ng/ml), BF occurred in 12% (18/150) and estimated actuarial BDFS at 36 
months was 78% (95%CI 67-92). BDFS at 2 years in patients who had re-do HIFU, 
was 66% (95% CI 43-100%). 
 
The 36-month Kaplan-Meier estimates regarding the primary and secondary 
outcomes have also been added in Table 6.  
 
Of the patients with biochemical failure, 62 had a mp-MRI in the follow-up, of which 
13 were negative. Of the 15 patients without an MRI in the follow-up, 1 died of 
disease unrelated to prostate cancer or the HIFU treatment, 8 received ADT (3 of 
which due to metastatic disease on a bone-scan and/or CT and 1 based on 
positive TPM-biopsies). Of 6 patients follow-up data was insufficient to assess the 
procedures after BF. Of the 49 patients with a recurrence on mp-MRI, all 
underwent either pelvic CT or radioisotope bone-scan to exclude metastatic 
disease. Patients potentially eligible for a second focal salvage HIFU procedure 
underwent subsequent TPM biopsies in all but 4 cases. 
 
Second, systemic therapy was started in 40.7% (61/150). 6.7% (10/150) had 
positive biopsy and 9.5% (9/150) developed distant metastases. 2.7% of patients 
(4/150) died of prostate cancer.  Mean time (±SD) to ADT following HIFU was 20 
(±15.9) months.  
 
Third, 12% (18/150) underwent biopsy post HIFU. This was positive in 55.6% 
(10/18). Of these 2/10 underwent salvage radical prostatectomy, 1/10 had ADT 
and then proceeded to have salvage radical prostatectomy and 3/10 were started 
on ADT. Overall, further treatment was performed in 14 patients; salvage radical 
prostatectomy (n=3), EBRT to spinal metastatic disease (n=1), irreversible 
electroporation (n=1), cryotherapy (n=1), chemotherapy (n=4) and other drug 
therapy (n=2). 
 
Fourth, there were 9 deaths  overall and four were prostate cancer-related. Kaplan-
Meier overall survival estimate at 60 months was 92% (95% CI 85-99%). One 
patient was high risk prior to radiotherapy and had Gleason 3+4 T3b disease prior 
to focal salvage HIFU. Post-HIFU his PSA continued to rise, he was started on 
hormones and went on to have further EBRT. The second was intermediate risk 
prior to radiotherapy and Gleason 4+4 and T3a disease prior to hemi-ablation 
salvage HIFU. Post-HIFU his PSA nadir was 0.0 ng/ml, he developed BF 15 
months later and went on to develop metastases 37 months later following BF. The 
third patient was high risk prior to radiotherapy and had PSA 4.12 ng/ml, Gleason 
4+3, and T3a disease prior to focal salvage HIFU. Post-HIFU his PSA rose to 5.63 
ng/ml and he was started on hormones and subsequent chemotherapy 24 months 
later. The fourth patient was high risk at baseline and had PSA 7.26 ng/ml, 
Gleason 4+5 and T2b disease prior to hemi-ablation salvage HIFU. Post-HIFU his 
PSA nadir was 0.11 ng/ml and he developed BF 9 months later and was started on 
chemotherapy at 54 months.  
 
Complications 
Fifth, complications included UTI in 11.3% (17/150), epididymitis in 1.3% (2/150), 
bladder neck strictures in 8% (12/150), rectourethral fistula after first HIFU in 2% 
(3/150) and osteitis pubis in 0.7% (1/150). For the men who experienced recto-
urethral fistula, one spontaneously resolved, one is being managed with urinary 
diversion with SPC and one has been surgically repaired (Table 4).  
 
Sixth, in those with available data from pre and post functional questionnaires 
(UCLA-EPIC, IPSS and IIEF-5), of those pad-free at baseline, 87.5% (42/48) 
remained pad-free at 2 years. 70.8% (34/48) were drip-free urinary continent at 
baseline and 67.6% (23/34) remained drip-free post-operatively at 2 years. 
Baseline IIEF scores were available for 31 men. 38.1% (12/31) men reported a 
baseline score >2 for Question 2 of IIEF which meant that erections were mostly 
sufficient for penetration. 58.3% (7/12) still had score of >2 at follow up (Table 5).  
 
 
Uni-and multivariable analyses for composite endpoint 
In univariable analyses, components that achieved statistical significance for the 
composite endpoint (CE) included primary Gleason Score 8-10 HR (95% CI) 1.88 
(1.06-3.32) p =0.03, time to radiological recurrence HR (95% CI) 0.989 (0.982-
0.996, p=0.002), T-stage 3 vs. T stage 1&2 pre-salvage HR (95% CI) 1.70 (1.09-
2.65) p=0.02,, pre-salvage PSA HR (95% CI) 1.06 (1.02-1.11 p=0.004), D’Amico 
pre-salvage high risk vs. low risk HR 2.57 (95% CI 0.89-7.38 P=0.08) and PSA-
nadir post-salvage HR (95% CI) 1.26 (1.19-1.32 p<0.0001). In multivariable 
analyses components that achieved statistical significance for the CE included T-
stage 3 vs. T stage 1 & 2 pre-salvage HR 1.96 (1.13-3.39) and PSA-nadir post-
salvage HR (95% CI) 1.29 (1.20-1.38) <0.0001. 
 
CEFS at 36 months (Table 6) in those with pre salvage HIFU PSA doubling time 
(PSADT) ≥12 months was 51%, (95%CI 37-70) vs. 24% (95% CI 14-41) p =0.003 
in those with PSADT <12 months  (Figure 3.2a) and 51% (95% CI 39-67) vs. 31% 
(95% CI 21-46 p=0.002) in men with pre-salvage HIFU PSA <5 ng/ml compared to 
those with pre-salvage HIFU PSA ≥5 ng/ml (Figure 3.2b). For men with MRI 
volume <25cc rates of composite free survival at 36 months was 48% (95%CI 35-
65) vs. 34% (95% CI 24-49 p=0.13) in those with MRI volume ≥25 cc (Figure 3.2c). 
In men with PSA nadir post salvage HIFU <0.5 ng/ml CEFS at 36 months was 67% 
(95% CI 53-82) vs. 21% (95% CI 13-33 p<0.0001) in those with PSA nadir ≥0.5 
ng/ml (Figure 3.2d).  
 
For the intermediate and high risk D’Amico groups composite-failure free survival 
at 36 months 49% (95% CI 36-68) and 24% (95% CI 14-40 p=0.006) respectively 
(Figure 4a). When the low and intermediate groups were combined, composite-
failure free survival at 36 months was 51% (95% CI 38-69) vs. high risk 24% (95% 
CI 12-38 p=0.001) (Figure 4b). 
 
Since low risk recurrences are uncommon, we have also performed multivariable 
analysis after excluding low risk D’Amico patients (n=4). Supplementary table 7 
reports on the multivariable analysis without D’Amico low risk patients included. 
For BF, MRI volume and PSA nadir post salvage remain statistically significant 
with low risk D’Amico patients excluded. For CE, PSA nadir post salvage HIFU 
remains statistically significant.  
 
Uni-and multivariable analyses for biochemical failure (Phoenix Definition) 
 
In univariable analyses components that achieved statistical significance for BF 
included primary Gleason Score 8-10 HR 2.06 (95% CI 1.10-3.85 p=0.02), time to 
radiological recurrence HR (95% CI) 0.988 (0.980-0.995, p=0.002), T-stage 3 vs. T 
stage 1&2 pre-salvage HR 1.78 (95% CI 1.11-2.87 p = 0.002), MRI volume HR 
1.014 (95% CI 1.003-1.025 p=0.01), PSA pre-salvage HIFU had HR 1.07 (95% CI 
1.02-1.12 p=0.003), and PSA-nadir after salvage HR 1.26 (95% CI 1.19-1.32 p = 
<0.0001). In multivariable analyses components that achieved statistical 
significance for BF included T-stage 3 vs. T stage 1&2 pre-salvage HR 1.99 (1.14-
3.46 p=0.02), MRI volume HR 1.014 (95% CI 1.002-1.027 p=0.03) and PSA-nadir 
after salvage 1.29 (95% CI 1.20-1.38 p = <0.0001). 
 
There were significant differences in BDFS (Table 6) at 36 months for men with a 
PSA doubling time of ≥12 months pre-salvage HIFU; 60% (95% CI 45-79) 
compared to 30% (95% CI 19-49 p=0.0005) with a PSA doubling time of <12 
months  (Figure 3a). For those with pre-salvage HIFU PSA <5 ng/ml compared to 
PSA ≥5ng/ml, BDFS was 62%, (95% CI 50-77) versus 37%, (95% CI 27-53 
p=0.0005) respectively (Figure 3b). Men with a prostate volume of <25cc prior to 
focal salvage HIFU, had a BDFS rate at 36 months of 60% (95% CI 47-77) 
compared with those with prostate volume ≥25cc; 41%, (95% CI 30-56 p=0.02) 
Figure 4c). At 36 months those who achieved PSA nadir of <0.5ng/ml had BDFS 
78%, (95% CI 67-92) compared with those who achieved a PSA nadir ≥0.5ng/ml; 
26%, (95% CI 17-39 p<0.0001) (Figure 4d).  
 
For the intermediate and high risk D’Amico groups BDFS at 36 months was 61% 
(95% CI 48-79) and 32% (95% CI 20-49 p=0.008) respectively (Figure 3c). When 
the low and intermediate groups were combined, BDFS rates at 36 months was 
62% (95% CI 49-79) vs. high risk 32% (95% CI 20-50 p=0.002) (Figure 3d). 
 
 
Discussion 
 
In summary, our results show that focal salvage HIFU has potential in the 
treatment of radiorecurrent prostate cancer. In our relatively high risk cohort, BF 
occurred in 52% (78/150). The Kaplan-Meier CEFS at 3 years was 40% (95% CI 
31-50%) for the entire group and 48% (95% CI 39-59%) for BFFS. The rate of 
side-effects seems to be lower than that conferred by whole-gland salvage 
therapies. Bladder neck strictures still occurred relatively frequent in this cohort 
(n=12 or 8%). Still, this percentage compares favourably to whole-gland salvage 
HIFU and salvage radical prostatectomy procedures, of which the bladder neck 
stricture rate is approximately 20% in the reported literature (6). However, the 
current bladder neck structure rate does compares somewhat unfavourable to 
other focal salvage series performed so far (6). On the other hand, these series 
have significantly less patients. Furthermore, due to the more broad patient 
selection in this study (including patients with seminal vesicle involvement), more 
extensive disease has potentially been treated, thereby increasing the risk of side-
effects. However, only comparative studies could provide a robust estimate of side-
effects of different salvage modalities.  
Our series therefore potentially reflects higher risk disease than other salvage 
series. This is observed in the median pre-focal salvage PSA of 5.5 ng/ml in our 
series. The mean/median PSA ranges from 2.8-5.5 in other focal salvage series 
reported in the literature (6). However, comparisons regarding D’Amico risk groups 
is more difficult, since these are usually not provided in the focal salvage series. 
 
It is apparent in this paper that higher risk patients can also benefit from focal 
salvage HIFU. Even though failure is still common and subsequent treatment 
initiated, in a substantial amount of patients follow-up whole-gland or systemic 
treatment can be postponed or prevented and quality of life therefore potentially 
improved.  
 
Excluding low risk D’Amico patients (n=4) further limits the patient sample and, for 
this reason coincidental statistical significance cannot be excluded. Therefore, the 
main statistical analysis was done including the low risk group. Furthermore, MRI-
volume and PSA-nadir after salvage remain the most significant and influential 
factors.  As a result, exclusion of low risk D’Amico group does not change factors 
associated with risk of BF or achieving the CE.  
 
Our study was pragmatic by not limiting the entry criteria for focal salvage HIFU 
other than to rule out metastatic disease or rule-out significant seminal vesicle 
invasion. We did not select men on an upper threshold such as PSA or PSA 
kinetics, we allowed many men with likely micro-metastatic disease to be treated. 
Our series therefore reflects higher risk disease that other salvage series.  As a 
result, we have been able to more robustly determine the upper limit of what is 
possible in a focal salvage strategy for future trial design and possible clinical 
practice. 
 
Also repeat treatment with a second HIFU was not classified as failure, as this was 
likely due to failure of adequate targeting during initial treatment as opposed to 
recurrence of disease post first focal salvage treatment. This was therefore 
classified as a completion of treatment. One of the key attributes for ablative 
therapies is the repeatability and the literature usually reports outcomes after 1-2 
ablative therapies.  
 
 
Limitations 
We had limited information on baseline and post operative erectile and urinary 
function despite issuing questionnaires to most men. Lack of baseline data may be 
due to no symptoms at initial consultation and therefore no assessment of 
symptoms using an objective method. Also as this was not conducted as part of a 
research trial, patients were not obligated to return questionnaires and this may be 
the reason for lack of responses. As this functional data was so frequently missing 
a valid conclusion is hard to link to the outcomes so far. Especially patients with 
severe deterioration might not have returned the questionnaires, thereby biasing 
the comparison in a significant way. Further, there is still some debate in the 
literature about radiation effect, delayed tumour regression and timing of biopsy 
post radiotherapy. Whilst there is some uncertainty, our team consists of expert 
uro-pathologists whose published work on clinically significant prostate cancer 
using different biopsy strategies primary and radiorecurrent setting (7,13-16)   . Our 
experts only report a Gleason Score when there is minimal radiation effect seen on 
the biopsies, and so feel that they are able to identify recurrent prostate cancer, 
when present, in radiation affected tissues with a high degree of accuracy and 
assign a grade to these.  
 
Nonetheless, focal salvage therapy for men following EBRT provides men with a 
further chance at cancer control that might avoid systemic therapies (17) and the 
morbidity of whole-gland salvage surgery or ablation. Salvage radical 
prostatectomy has been reported to have 5 year BDFS rates of between 47% to 
82% (2), complications such as rectal injury (0-28%) (2,18)  and rates of 
incontinence (21- 90%) (2) and erectile dysfunction (80-100%) (2) are high due to 
fibrosis and poor wound healing due to radiation. A systematic review of salvage 
focal cryotherapy found biochemical disease-free survival of 50-68% at 3 years, 
rectourethral fistula rates of 0% and ED occurred in 60-71% (19). BDFS rates 
following whole gland salvage HIFU are 25-53% (20,21) . Incontinence (10–50 %), 
erectile dysfunction 66.2–100 % and recto-urethral fistula (3–16 %) have also been 
reported (20-22)  . Overall, functional outcomes are generally poorly reported in the 
literature due to the retrospective nature of the studies.  
 
A further limitation of the study is that no validated definition for failure is available 
in the (focal) salvage setting after radiotherapy failure. Therefore, a composite 
endpoint was chosen as a combined failure definition, incorporating biochemical 
outcomes, imaging (multiparametric MRI, [Choline-PET]/CT, radioisotope bone 
scan), biopsy results, systemic therapy initiation and metastatic disease/prostate 
cancer specific mortality. This definition more clearly reflects failure in the early to 
medium term after focal salvage since the Phoenix definition is not validated in the 
focal salvage setting and can be biased due to ADT use before focal salvage, 
which was present in a substantial amount of patients (n=68).  
 
However, the estimates from the Kaplan-Meier analyses and multivariable 
analyses are very similar for BF and the CE, potentially indicating the validity of a 
failure definition based on biochemical outcomes. This is also visible in the 
verification of BF with mostly MRI (n=51) or biopsies (n=11). However, 13 patients 
still achieved the composite recurrence outcome without previous BF. In the 
absence of a clear failure definition, we therefore recommend subsequent imaging 
and biopsy verification of patients with BF after focal salvage HIFU.  Indeed 
another limitation of this study is the absence of detailed criteria for response 
assessment or adoption of subsequent diagnostic modalities in case of disease 
progression. However, most patients (62/77) with BF received mp-MRI in case of 
BF after focal salvage HIFU. Results of mp-MRI in the radiorecurrent setting are at 
least equal, if not better, which is hypothesized to be due to increased contrast of 
tumour with the surrounding fibrotic prostate tissue. Negative and positive 
predictive values of up to 90-95% are described (23-27)   ,) We have also 
demonstrated very high negative predictive values of a post-treatment MRI in men 
treated with focal HIFU who all underwent a biopsy within a clinical trial . To our 
knowledge, there are no results of mp-MRI and/or biopsies in the setting after both 
radiotherapy and focal salvage HIFU in the literature. 
 
It is quite clear that prospective studies are required. Our FORECAST - Focal 
Recurrent Assessment and Salvage Treatment for Radiorecurrent Prostate Cancer 
(28) - study will examine focal salvage cryotherapy and HIFU as well as the role of 
imaging in ruling out metastatic disease and diagnosing local recurrence. We are 
also planning comparative studies although these are often difficult to accrue to 
(29). 
 
Conclusion  
Focal salvage HIFU confers a relatively low complication and side-effect rate. 
Composite endpoint free survival and biochemical control in the short to medium 
term is reasonable, especially in this relatively high risk cohort, but still on the lower 
end compared to current whole gland salvage therapies. Focal salvage therapy 
may offer disease control in high risk men whilst minimising additional treatment 
morbidities. 
Appendix 
Figure 1 - Methods of focal ablation 
 
 
 
a) Posterior quadrant salvage ablation to a single lesion with focal salvage 
HIFU  
b) Hemi ablation of index lesion to two Index lesions with focal salvage HIFU 
whilst leaving low risk cancer untreated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical methods 
 
Model development: Missing data was considered at random and handled using 
multiple imputation by means of the iterative Markov chain Monte Carlo method 
with a total of 20 iterations (30).  Predictor variables used for the imputation 
procedure were all variables as described above. The outcomes were included as 
well. Cox-proportional hazards regression was used to quantify the effect of the 
determinants on the endpoints. Hazard ratios (HRs) with 95% confidence intervals 
(CI’s) are provided. Factors with a p-value on univariable analysis ≤0.05 based on 
the Wald-test statistic were included in the multivariable model. Proportionality of 
the cumulative hazard functions was evaluated with Schoenfeld residuals for 
continuous variables and log-log curves (+ Shoenfeld residuals) for categorical 
variables. Martingale residuals were used to assess linearity of continuous 
variables and dfBeta residuals to assess influential outliers. Interactions were not 
assessed.  The R language environment (version 3.2.1) (available at http://www.r-
project.org/) (12,31,32)  was used for all statistical analyses and population of Kaplan-
Meier curves for biochemical disease free survival and freedom from composite 
end point (using the survival and rms package  .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1 - Baseline characteristics at time of radiotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics before primary radiation treatment 
 
 
Number 
 
%/IQR/SD 
 
Missing 
(%) 
Primary therapy    
     EBRT 145 96.7% 0% 
     EBRT+HDR-BT boost 5    3.3% 0% 
Initial PSA before primary treatment (ng/ml), median 
(IQR) 
13.9  8.9-26.3 10% 
D’Amico risk group    14% 
1 - High risk PSA 20, Gleason Score ≥8 and T2c-T3a 63 42% 
2 - Intermediate risk PSA 10-20, Gleason Score 7 or T2b 
disease 
35 23.3% 
3 - PSA<10, Gleason Score ≤6 and T1-2a 31 20.7% 
ADT use (cytoreduction/adjuvantly or neo-adjuvantly) 106 71% 1.3% 
Abbreviations: EBRT=External beam radiotherapy; HDR=High dose rate; 
BT=Brachytherapy; PSA=Prostate specific antigen; IQR=Interquartile range; 
SD=Standard deviation; ADT=Androgen deprivation therapy. 
 Table 2 - Pre-focal salvage HIFU characteristics 
 
 
  
Number 
 
%/IQR/SD/
95% CI 
 
Missing 
(%) 
Age (years) at focal salvage treatment, mean 
(±SD) 
69.8 ±6.1 0% 
PSA pre-salvage (ng/ml), median (IQR) 5.5 3.6-7.9 0.7% 
Radiological T-stage pre-salvage    
      T1 11 7.3%  
1.3%       T2 102 68% 
      T3 35 23.3% 
Gleason grade pre-salvage    
      Gleason 2-6 8 5.3%  
 
2.7% 
      Gleason 3+4 72 48% 
      Gleason 4+3 39 26% 
      Gleason 8-10 27 18% 
Biopsy type    
      TPM biopsies 104 69.3%  
3.3%       TRUS-guided biopsies 40 26.7% 
     MRI guided 1 0.7% 
D’Amico risk group pre-salvage    
1 - High risk PSA > 20, Gleason Score≥8 and T2c-
T3a 
62 41.3% 16.7 
2 - Intermediate risk PSA 10-20, Gleason Score 7 
or T2b disease 
59 39.3% 
3 - PSA<10, Gleason Score ≤6 and T1-2a 4 2.7% 
ADT pre-salvage 68 45% 0% 
Abbreviations:  IQR=Interquartile range; SD=Standard deviation; CI=Confidence 
interval; Tx=Treatment; TPM=Template prostate mapping; TRUS=Transrectal 
ultrasound; PSA=Prostate specific antigen. 
Table 3 - Outcomes post focal salvage HIFU 
 
 
 
 
Table 4 - Toxicity outcomes  
Clavien 
Grade 
Definition No. of 
patients 
(%) 
1 Any deviation from the normal intraoperative or postoperative 
course, including the need for pharmacologic treatment other 
than antiemetics, antipyretics, analgesics, diuretics, 
electrolytes, or physiotherapy 
19 (12.7%) 
2 Complications needing only the use of intravenous 
medications, total intravenous nutrition, or blood transfusion 
0 (0) 
3a Complications needing surgical, endoscopic, or radiologic 25 (16.3%) 
 
 
 
Number 
 
%/IQR/SD/
95% CI 
 
Missing 
(%) 
Method of ablation    
 
0% 
      Focal ablation 82 55% 
      Hemi-ablation 51 34% 
      Index lesion ablation (with residual cancer left    
untreated) 
17 11% 
Composite endpoint (BF, ADT, MRI+, biopsies + 
systemic treatment + metastases +, prostate cancer 
specific mortality ) 
91 60.7% 0% 
BF (Phoenix definition) 77 51.3% 0% 
PSA-nadir after salvage (ng/ml), median (IQR) 0.67 0.2-1.9 2.7% 
Follow-up (months) from salvage, median (IQR) 35 22-52 0% 
Death 
     Overall 
     Prostate cancer specific 
9 
5 
4 
6% 
3.3% 
2.7% 
0% 
Abbreviations:  BF=Biochemical failure; ADT= Androgen deprivation therapy;  
IQR=Interquartile range; PSA=Prostate specific antigen. 
intervention under local anaesthesia 
3b Complications needing surgical, endoscopic, or radiologic 
intervention under general anaesthesia 
16 (11%) 
4a Life-threatening complications requiring intensive care unit 
management: Single-organ dysfunction 
0 (0) 
4b Life-threatening complications requiring intensive care unit 
management: Multiorgan dysfunction 
0 (0) 
5 Death of the patients 0 (0) 
 
 
Table 5 Functional outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
Functional outcomes Pre-focal 
salvage  
Post-focal 
salvage (6-
36) months 
IPSS median (IQR) 8 (4-15)  11 (7-18)  
   
Drip free status  67% 
(50/75) 
46% (28/61) 
   
Pad-free status 97% 
(70/72) 
78% 
(46/59) 
   
IIEF Q2 Score >2 % (n=31) 38% 
 (n=12) 
22% 
 (n=7) 
   
IIEFF Score median (IQR) 15 (7-39) 
(n=54) 
13 (7-24) 
(n=42) (3-72 
months) 
   
PDE-5 use  21% 
(12/57) 
24% 
(11/45) 
Abbreviations: IPSS=International prostate symptom score; IIEF=International 
index of erectile function; PDE-5=Phosphodiesterase type 5 inhibitor. 
Table 6 – Kaplan – Meier estimates for composite endpoint free survival rates 
(CEFS) and biochemical disease free survival (BDFS) rates at 36 months  
 CEFS (95% CI) BDFS (95% CI) 
Entire group 40% (31-50%) 48% (39-59%) 
D’Amico low risk 100% (NA) 100% (NA) 
D’Amico intermediate risk 49% (36-68%) 61% (48-79%) 
D’Amico high risk 24% (14-40%) 32% (20-49%) 
D’Amico low +intermediate 
risk 
51% (38-69%) 62% (49-79%) 
D’Amico high risk 24% (14-40%) 32% (20-49%) 
PSA nadir < 0.5 ng/ml 67% (53-82%) 78% (67-92%) 
PSA nadir ≥ 0.5 ng/ml 21% (13-33%) 26% (17-39%) 
PSADT ≥ 12 months 51% (37-70%) 60% (45-79%) 
PSADT < 12 months 24% (14-41%) 30% (19-49%) 
PSA < 5 ng/ml 51% (39-67%) 62% (50-77%) 
PSA ≥ 5 ng/ml 31% (21-46%) 37% (27-53%) 
Prostatic volume < 25 cc 48% (35-65%) 60% (47-77%) 
Prostatic volume ≥ 25 cc 34% (24-49%) 41% (30-56%) 
Abbreviations: CEFS=Composite endpoint free survival; BDFS=Biochemical 
disease free survival; PSA=Prostate specific antigen; PSADT=Prostate 
specific antigen doubling time. 
 
Supplementary Table 7: Multivariable analysis for biochemical failure and the 
composite endpoint without D’Amico low risk patients 
 
Determinants 
BF 
HR (95% CI) p-value Determinants 
CE 
HR (95% CI) p-value 
MRI volume 1.01 (1.001-
1.028) 
0.03    
PSA-nadir 
post-salvage 
1.28 (1.19-
1.38) 
<0.0001 PSA-nadir 
post-salvage 
1.28 (1.19-
1.38) 
<0.0001 
Abbreviations: BF=Biochemical Failure; HR=Hazard Ratio; CI=Confidence Interval; 
CE=Composite Endpoint; PSADT=PSA-doubling time. 
 
 
 
 
  
Figure 3 – Composite endpoint free survival (CEFS) 
 
 
 
Figure 2a - CEFS for PSA doubling time pre-focal salvage HIFU 
Figure 2b - CEFS for pre-focal salvage HIFU PSA 
Figure 2c - CEFS by MRI volume 
Figure 2d - CEFS for PSA nadir post-focal salvage HIFU  
 
 
 
 
 
 
 
 
 
Figure 3 – Biochemical disease free survival (BDFS) rates 
 
 
 
Figure 3a - BDFS for PSA doubling time pre-focal salvage HIFU 
Figure 3b - BDFS for pre-focal salvage HIFU PSA 
Figure 3c - BDFS by MRI Volume 
Figure 3d - BDFS for PSA nadir post-focal salvage HIFU  
 
 
 
 
 
 
 
 
 
Figure 4 - Biochemical disease free survival (BDFS) and Composite endpoint 
free survival (CEFS) according to D’Amico classification pre-focal salvage 
HIFU 
 
 
 
Figure 4a  - CEFS by D’Amico risk group pre-focal salvage HIFU 
Figure 4b - CEFS by D’Amico low and intermediate combined vs. high risk 
group pre-focal salvage HIFU  
Figure 4c - BDFS by D’Amico risk group pre-focal salvage HIFU 
Figure 4d - BDFS by D’Amico low and intermediate combined vs. high risk 
group pre-focal salvage HIFU 
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